Non-Hodgkin Lymphoma Treatment Market by Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy), Application (Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma), End-User - Global Forecast 2024-2030

Non-Hodgkin Lymphoma Treatment Market by Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy), Application (Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma), End-User - Global Forecast 2024-2030

The Non-Hodgkin Lymphoma Treatment Market size was estimated at USD 8.20 billion in 2023 and expected to reach USD 8.84 billion in 2024, at a CAGR 7.91% to reach USD 13.98 billion by 2030.

Non-Hodgkin Lymphoma refers to a type of cancer that begins and develops in the lymph nodes and lymphatic tissue found in organs, including the stomach and intestines. Swollen lymph nodes in the neck, abdominal pain or swelling, chest pain, coughing, or trouble breathing are some common symptoms of the disease. Treatment options for non-Hodgkin lymphoma (NHL) include chemotherapy, radiation, plasmapheresis targeted therapy, and stem cell transplant. Newer treatment options for non-Hodgkin lymphoma are focused on making personalized medications, targeted drugs, and immunotherapy engineered to attack cancer cells specifically. Changing lifestyles and rising incidences of obesity have led to a surge in the number of patients suffering from cancers and tumors. Additionally, the launch of promising drugs and the number of drug approvals for lymphomas is rapidly increasing. However, the high cost of availing cancer treatment options reduces the accessibility of treatment options. Furthermore, stringent regulations for cancer treatment options have dissuaded research institutions from investing in cancer treatment research and have hampered the commercialization of novel drugs. The government's focus on increasing awareness about cancer and its treatment options is gaining traction and can aid in reducing the number of barriers posed by complex regulations. Biotechnology, and pharmaceutical institutions and companies have introduced targeted biological therapies and drug options for cancer, such as antibody-drug conjugate and proteasome inhibitors.

Regional Insights

Significant Americas countries, such as the USA and Canada, are associated with a higher awareness of the availability of treatment options and reimbursement plans for cancer treatment. The Americas market for NHL treatment is driven by the increasing number of cancer care centers and oncology specialists in the region. Additionally, Americas countries are characterized by the presence of major biotechnology and pharmaceutical companies and a large number of treatment solutions introduced for Non hodgkin lymphoma. Countries in Asia, including China, have expanded their focus on increasing the number of drug approvals for cancer treatment. Governments are rapidly investing their efforts to improve awareness of lymphomas and their symptoms. European nations have well-established academic and research institutions that are actively involved in research and development activities concerning non-Hodgkin lymphoma and other cancers. Additionally, the growing number of clinical trials and collaborations between biotechnology companies and governments has been a significant driving factor towards the introduction of novel treatment therapies.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Non-Hodgkin Lymphoma Treatment Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

Rising prevalence of non-Hodgkin lymphoma disease
The launch of promising drugs and drug approval for lymphomas
Emphasis on NHL patient prognosis and standard of care in front-line treatment regimens

Market Restraints

High cost of the treatment and certain side effects

Market Opportunities

Increase in research and development of therapeutic drugs against the disease
Rising investments from government and non-profit organizations

Market Challenges

Stringent regulations for cancer treatment options

Market Segmentation Analysis

Treatment type: Chemotherapy treatments to prevent the spread of cancer to other parts of the body
Application: Utilization of immunotherapy and radiation in advanced stages treatment of diffuse large B cell lymphoma (DLBCL)
End-user: Increasing adoption of novel strategies for NHL treatment in hospitals

Market Disruption Analysis

Porter’s Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Non-Hodgkin Lymphoma Treatment Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Non-Hodgkin Lymphoma Treatment Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

EPKINLY (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

AbbVie Inc. has announced that the U.S. Food and Drug Administration (FDA) has recently granted approval for EPKINLYTM (epcoritamab-bysp) for the treatment of diffuse large B-cell lymphoma (DLBCL) in adults. This includes DLBCL that arises from high-grade B-cell lymphoma and indolent lymphoma after two or more lines of systemic therapy. EPKINLY is the only T-cell-engaging bispecific antibody for non-Hodgkin lymphoma treatment approved by the FDA.

Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies

Janssen Biotech Inc., a Johnson & Johnson Services, Inc. subsidiary, collaborated with Cellular Biomedicine Group Inc. (CBMG) on developing and commercializing CAR T-cell therapies specifically designed for B-cell malignancies. These autologous CAR-Ts, directed towards CD20, have exhibited promising response rates in Phase 1 clinical trials involving non-Hodgkin's lymphoma (NHL) patients. This collaboration between Janssen Biotech Inc. and Cellular Biomedicine Group Inc. represents a significant step forward in advancing CAR T-cell therapies for treating B-cell malignancies, particularly in the context of non-Hodgkin lymphoma.

Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration

Biogen Inc. and Genentech, a Roche Group member, have agreed on the commercialization and economic sharing of glofitamab, a non-Hodgkin lymphoma treatment. Under this agreement, Biogen receives tiered royalties based on potential net sales in the United States without any payment obligations. This partnership revolves around developing an antibody that targets CD20 and extends the existing collaboration between both companies.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Non-Hodgkin Lymphoma Treatment Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Non-Hodgkin Lymphoma Treatment Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Aurobindo Pharma, Bayer AG, Cipla Inc., Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Hetero Drugs Ltd., Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Janssen Global Services, LLC, Kyowa Kirin Co., Ltd., Lupin Ltd., Merck KGaA, Nordic Nanovector ASA by Thor Medical, Novartis AG, Pharmacyclics, LLC, Salvavidas Pharmaceutical Pvt. Ltd., Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Zydus Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Non-Hodgkin Lymphoma Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

Treatment Type
Chemotherapy
Immunotherapy
Radiation Therapy
Stem Cell Transplantation
Targeted Therapy
Application
Diffuse Large B-cell Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma
End-User
Cancer Centers
Home Care
Hospitals
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year